Juul asks court for temporary block on FDA’s ban of its e-cigarettes

Juul asks court for temporary block on FDA’s ban of its e-cigarettes


Juul brand vape cartridges are pictured for sale at a shop in Atlanta, Georgia.

Elijah Nouvelage | Reuters

Juul asked a federal appeals court on Friday to block the Food and Drug Administration’s ban on its e-cigarettes temporarily.

The request came less than a day after the health agency told the company that it had to pull its vaping products off the U.S. market, effective immediately. According to the FDA, Juul’s applications to keep selling its vaping device and menthol- and tobacco-flavored nicotine pods gave insufficient or conflicting data about the potential risks of using the company’s products.

Juul disagreed, saying in a statement that it provided sufficient research and evidence to address the issues raised by the agency. The company’s chief regulatory officer, Joe Murillo, said in a statement on Thursday that Juul is exploring its options, which include appealing the decision or engaging with the FDA.

In a filing with the U.S. Court of Appeals for the D.C. Circuit, Juul asked for an emergency administrative stay until it can file a motion for a stay pending review by noon on Monday. If granted, the company and retailers would be able to keep distributing and selling Juul products until the court reviews the agency’s decision.

“[Juul’s] only prospect for meaningful relief that permits it to continue selling its products is an immediate stay,” the company said in the filing.

Juul claimed that the FDA subjected it to unfair treatment compared with other e-cigarette makers. According to the filing, the agency’s press release announcing its ruling on Juul products was “more strident and threatening” than previous denials.

“FDA’s decision is arbitrary and capricious and lacks substantial evidence, and an immediate administrative stay is critical to protect JLI, its commercial partners, and its customers,” Juul said.

The company also called out the agency for imposing immediate enforcement, rather than instating a transition period, which is typical unless the product poses an immediate risk to consumers.

The FDA declined to comment.



Source

UnitedHealth Group shares plunge 18% on reported DOJ probe into possible Medicare fraud
Health

UnitedHealth Group shares plunge 18% on reported DOJ probe into possible Medicare fraud

Bloomberg | Bloomberg | Getty Images Shares of UnitedHealth Group plunged more than 18% on Thursday following a report that the Justice Department is conducting a criminal investigation into the health-care giant over possible Medicare fraud. The DOJ is focusing on the company’s Medicare Advantage business practices, but the exact nature of the potential criminal […]

Read More
Kennedy sidesteps vaccine questions: ‘I don’t think people should be taking medical advice from me’
Health

Kennedy sidesteps vaccine questions: ‘I don’t think people should be taking medical advice from me’

Health and Human Services Secretary Robert F. Kennedy Jr. on Wednesday sidestepped a question about vaccines and whether he would choose to vaccinate his children today against a number of diseases, saying, “I don’t think people should be taking medical advice from me.” Kennedy’s comment was in response to Rep. Mark Pocan, D-Wis., during a […]

Read More
Healthy Returns: Trump provides a glimpse of the third round of Medicare drug price negotiations
Health

Healthy Returns: Trump provides a glimpse of the third round of Medicare drug price negotiations

In a photo illustration, prescription drugs are seen next to a pill bottle on July 23, 2024 in New York City. Spencer Platt | Getty Images News | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to […]

Read More